|Day Low/High||2.24 / 2.28|
|52 Wk Low/High||1.46 / 8.05|
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CTRN, FSFG, LWAY Downgrades: BAM, BT, DHT, RFIL, SNP Initiations: FATE Read on to get TheStreet Quant Ratings' detailed report:
Phase 1/2 Clinical Trial of ProTmune for Prevention of Acute GvHD and CMV Infection Now Open for Enrollment
These stocks look ready to break out and trade higher from current levels.
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Multi-Center, Randomized, Controlled Phase 1/2 Clinical Trial in Mobilized Peripheral Blood HCT to be Initiated in Mid-2016
Proprietary Pluripotent Cell Platform for Engineered Adoptive Immunotherapies to be Highlighted During Two Poster Sessions